Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,087 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-Müllerian hormone type II receptor protein expression in non-small cell lung cancer and the effect of AMH/AMHR2 signaling on cancer cell proliferation.
Koinuma Y, Mitsuishi Y, Winardi W, Hidayat M, Wirawan A, Hayakawa D, Kanamori K, Matsumoto N, Hayashi T, Shimada N, Tajima K, Takamochi K, Takahashi F, Suzuki K, Takahashi K. Koinuma Y, et al. Among authors: takahashi k, takahashi f. Thorac Cancer. 2024 Sep 4. doi: 10.1111/1759-7714.15309. Online ahead of print. Thorac Cancer. 2024. PMID: 39230026 Free article.
Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D, Takahashi F, Mitsuishi Y, Tajima K, Hidayat M, Winardi W, Ihara H, Kanamori K, Matsumoto N, Asao T, Ko R, Shukuya T, Takamochi K, Hayashi T, Suehara Y, Takeda Nakamura I, Ueno T, Kohsaka S, Mano H, Takahashi K. Hayakawa D, et al. Among authors: takahashi k, takahashi f. Thorac Cancer. 2020 Jan;11(1):140-149. doi: 10.1111/1759-7714.13255. Epub 2019 Nov 22. Thorac Cancer. 2020. PMID: 31758670 Free PMC article.
Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y, Ko R, Shimada N, Mitsuishi Y, Miura K, Matsumoto N, Asao T, Shukuya T, Shibayama R, Koyama R, Takahashi K. Miyashita Y, et al. Among authors: takahashi k. Thorac Cancer. 2021 Feb;12(3):329-338. doi: 10.1111/1759-7714.13742. Epub 2020 Nov 21. Thorac Cancer. 2021. PMID: 33219754 Free PMC article.
Zinc-finger E-box-binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib.
Nurwidya F, Takahashi F, Winardi W, Tajima K, Mitsuishi Y, Murakami A, Kobayashi I, Nara T, Hashimoto M, Kato M, Hidayat M, Suina K, Hayakawa D, Asao T, Ko R, Shukuya T, Yae T, Shimada N, Yoshioka Y, Sasaki S, Takahashi K. Nurwidya F, et al. Among authors: takahashi k, takahashi f. Thorac Cancer. 2021 May;12(10):1536-1548. doi: 10.1111/1759-7714.13937. Epub 2021 Mar 25. Thorac Cancer. 2021. PMID: 33764690 Free PMC article.
CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma.
Kanamori K, Suina K, Shukuya T, Takahashi F, Hayashi T, Hara K, Saito T, Mitsuishi Y, Shimamura SS, Winardi W, Tajima K, Ko R, Mimori T, Asao T, Itoh M, Kawaji H, Suehara Y, Takamochi K, Suzuki K, Takahashi K. Kanamori K, et al. Among authors: takahashi k, takahashi f. Thorac Cancer. 2023 Apr;14(12):1089-1097. doi: 10.1111/1759-7714.14853. Epub 2023 Mar 16. Thorac Cancer. 2023. PMID: 36924358 Free PMC article.
Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A, Nurwidya F, Yae S, Koizumi F, Moriyama H, Seyama K, Nishio K, Takahashi K. Minakata K, et al. Among authors: takahashi k, takahashi f. Cancer Sci. 2012 Nov;103(11):1946-54. doi: 10.1111/j.1349-7006.2012.02408.x. Epub 2012 Sep 14. Cancer Sci. 2012. PMID: 22863020 Free PMC article.
17,087 results
You have reached the last available page of results. Please see the User Guide for more information.